Can patient advocates be your best investors? Current and future biotech entrepreneurs take note: if your startup is aligned with a venture philanthropist's mission, you can tap into huge pools of money, expertise, and energy. Check out my paper with former student Dan Alvarez!

Looking forward to joining the "Building a Functional Precision Medicine Company" panel this Saturday at 3:25 with Carla from SEngine Precision Medicine, Andrea Mazzocchi from Known Medicine, and Cliff Read from Travera. Thanks to Keith Ligon for moderating. Registration is free! #AACR22

SAFEs, but for Series A, B, C, etc. Standardized the docs for preferred rounds. This would usher in an era of venture rounds not bound by a ‘lead’ investor.

I have found all of these points to be true, and especially important if your presentations include scientific data (very common for slides to be crammed with every figure which immediately breaks the one idea per slide rule, not to mention the jargon problem…)

Lots of movement from top names to back more founders with tech + vision in biotech. This balance returning will be much healthier for our industry and allow for more ambitious leaps forward than logical incremental steps. Very excited for the future of biotech!

required watching for founders from David Sacks youtu.be/xU0F8VZj_cY

We're excited to announce positive initial data from the ongoing, pivotal Phase 2 FIREFLY-1 clinical trial. Join us tomorrow at 8 a.m. EST for our conference call and webcast. ir.dayonebio.com/news-releases/…

Having survived two previous market resets (2001, 2009), people frequently ask me how this 2022 market reset is different and how it is the same. The obvious similarity is that valuation multiples have collapsed. We went from a "glass very full" mindset to one with many concerns.

I'm so excited to be launching Vibe Bio - a new biotech company founded by Joshua Forman & myself to give patients with #rare + overlooked diseases access to the funding and community they need to develop treatments. vibebio.com

We are delighted to announce that Endpoint Health was selected for the 2022 Y Combinator Top Companies list. Learn more about this honor and about our company: bit.ly/3AGveF3

We are really excited to announce our series A fundraise led by Builders VC to support our on-going efforts to drug transcription and bring new medicine to patients with Rare Disease and Cancer. Joey Azofeifa #startup #biotech #BiotechNews businesswire.com/news/home/2022…

BIOS — Top 100 TechBio VC Funds 🧬 As TechBio reaches critical mass, we thought it time to centralize the world of TechBio VC into one sheet We hope this database becomes a useful resource & serves as a go to for founders raising VC Funding… ow.ly/GCCy50KSvaO

A new software stack is emerging for the $230B life sciences R&D industry to match the incredible scientific progress of the past decade. I explored the new workflow, infrastructure and AI tools behind this stack here: vitalsignshealth.substack.com/p/the-changing…

Catch me 11am tomorrow in The Newsroom at #HLTH2022 where I drop some unpopular facts about the state of maternal and child health in the US - tl;dr I am the statistic

Functional precision medicine company Notable is soon to be public via merger.... look for NASDAQ:NTBL. Big news for the growing #fpm field and congrats to founder and friend Matthew De Silva seekingalpha.com/news/3939874-v… #PrecisionOncology #sfpm

Congratulations to our CEO at Pathos Ryan Fukushima on being included in the Endpoints News 20 under 40 list today

We are proud to be selected by the Endpoints News editorial team as one of the most promising and ambitious #biotech startups! We’re grateful for the recognition of what we’ve built so far and where we are headed next: the clinic in 2024! endpts.com/the-endpoints-…

Today, I’m thrilled to announce the launch of my new firm, Ritual Capital, a $38M seed-stage venture firm investing collaborative $300k checks in exceptional founding teams building iconic, enduring companies. ritualcapital.com

Waiting till your 40s or 50s to be a first-time biotech CEO is terrible advice to give young scientist entrepreneurs. You’re supposed to be in your 20s and 30s when you start your first company! That’s the fucking point: learn, fail, pivot, again and again and again.

Delighted to share the news of our partnership with Boehringer Ingelheim India. This is largely the hard work of Jack Castle, Quin Wills and the wider R&D team. I feel v grateful to work with such talented people to improve treatment options for liver disease patients. endpts.com/boehringer-ing…